[Role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis].

1. Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahasi N, Sanderson S, et al. Drug-induced autoimmune hepatitis: clinical characteristic and prognosis. Hepatology. 2010;51:2040–8. 2. Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol. 2006;40:757–61. 3. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958–76. 4. Lucena MI, García-Martín E, Andrade RJ, Martínez C, Stephens C. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology. 2010;52:303–12. 5. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117–26. 6. Björnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic druginduced liver injury with jaundice. J Hepatol. 2009;50:511–7. 7. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut. 1999;44:731–5. 8. Ohmoto K, Yamamoto S. Drug-induced liver injury associated with antinuclear antibodies. Scand J Gastroenterol. 2002;11:1345–6.